A compact, spoonable food matrix designed to deliver meaningful protein and energy in small portions for people with reduced intake during GLP-1 therapy. Each 125 g serving targets 200 kcal and 15 g protein, with engineered starch, protein, and lipid structures to moderate carbohydrate digestion while preserving nutrient accessibility.
This research opportunity focuses on compact, nutrient-dense food matrices designed to help people with reduced food intake during GLP-1 therapy obtain meaningful protein and energy from small, acceptable portions. The initial target is a smooth, spoonable 125 g serving providing approximately 200 kcal and 15 g protein, with digestible carbohydrates, moderate fat, and selected micronutrients.
The approach combines food-matrix architecture and conventional processing to moderate early carbohydrate digestion while preserving overall nutrient accessibility and an easy-to-consume texture. By engineering starch structure, protein interactions, and lipid dispersion, the matrices aim to support more sustained energy delivery. Structured prototypes will be compared with composition-matched controls to establish whether matrix design adds value beyond ingredient composition. This evidence base is intended to guide subsequent human studies of gastrointestinal tolerance and sustained physical energy.
The proposed proof-of-concept will develop and evaluate compact formulations with the following features:
The project plan includes developing 6–8 initial formulations, screening them to select three lead prototypes, producing those leads in three independent batches, and generating prototype specifications, processing protocols, comparative data, and jointly agreed go/no-go criteria for pilot development.
This is an early-stage proof-of-concept at laboratory scale. No human validation has been completed. The proposed eight-month project would establish formulation feasibility, characterize digestion kinetics and nutrient accessibility, and assess sensory, stability, and scale-up potential. On successful completion, the evidence would support pilot development and subsequent human evaluation of GI tolerance and sustained-energy outcomes.
Tecnológico de Monterrey is a leading private, multi-campus research university in Mexico, recognized for entrepreneurship and industry collaboration. Its Monterrey headquarters anchors an urban innovation district with open lab space, prototyping, and shared testing facilities that welcome corporate collaborators. An integrated health system supports clinical research and translation, while structured internships and challenge-driven partnerships connect companies with faculty and student talent year-round. Research is supported by competitive federal funding through Mexico’s national science and technology council, along with industry contracts and international sponsors. A dedicated technology transfer office manages IP, licensing, and startup formation.